Document is current
Any future updates will be listed below
-
Authors
Herrejon Chavez, Florisela http://orcid.org/0000-0003-2238-0369
Luo, Hanzhi
Cifani, Paolo
Pine, Alli
Chu, Eren L.
Joshi, Suhasini
Barin, Ersilia
Schurer, Alexandra http://orcid.org/0000-0001-8028-838X
Chan, Mandy
Chang, Kathryn
Han, Grace Y. Q.
Pierson, Aspen J.
Xiao, Michael
Yang, Xuejing
Kuehm, Lindsey M.
Hong, Yuning
Nguyen, Diu T. T.
Chiosis, Gabriela http://orcid.org/0000-0003-0486-6920
Kentsis, Alex
Leslie, Christina http://orcid.org/0000-0002-4571-5910
Vu, Ly P. http://orcid.org/0000-0002-1682-7702
Kharas, Michael G. http://orcid.org/0000-0002-1165-6991
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL135564)
- License Information
-
More Information
Article History
Received: 23 April 2022
Accepted: 11 April 2023
First Online: 21 April 2023
Competing interests
: A.K. is a consultant to Rgenta, Novartis, and Blueprint Medicines. M.G.K. is a SAB member of 858 Therapeutics and received honorarium from Kumquat, AstraZeneca and Consultancy with Transition Bio. The remaining authors declare no competing interests.
